Gates Foundation makes its biggest-ever equity investment in German biotech
Friday, March 6, 2015
The Bill & Melinda Gates Foundation said it would invest $52 million in CureVac, a German biotechnology company that develops vaccines and immunotherapies, marking the foundation’s biggest-ever equity investment.
Privately held CureVac uses its proprietary mRNA technology, which allows for rapid low-cost production of drugs and vaccines, to teach the human body to produce proteins capable of fighting a wide range of diseases.
The investment will support development of CureVac’s technology and the construction of a production facility. CureVac and the foundation will also collaborate to develop vaccines to fight infectious disease.
Source: Reuters (link opens in a new window)
- Health Care